Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITUXILUP vs EUROLUPUS in Proliferative Lupus Nephritis
NCT05207358Phase 4Recruiting
- Sponsor
- Fundeni Clinical Institute
- Start
- Mar 2022
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in lupus nephritis (LN), sponsored by Fundeni Clinical Institute. Started Mar 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05207358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207358.